SpringWorks Therapeutics Inc. (SWTX) – Analyst Ratings
-
Guggenheim Starts Spring Works Therapeutics (SWTX) at Buy
-
Spring Works Therapeutics (SWTX) PT Raised to $52 at Goldman Sachs
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to SWTX Stock Lookup